Page 6 - Briefing Document News Today

Share this article Share this article RADNOR, Pa., May 24, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). Investor Reminder:  Investors who purchased or acquired ChemoCentryx common stock...

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. RADNOR, Pa., May 19, 2021 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP reminds ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against ChemoCentryx on behalf of those who purchased or acquired ChemoCentryx common...

Share this article Share this article NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May...

Home / Top News / Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Peloton, Repro Med, and ChemoCentryx and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Peloton, Repro Med, and ChemoCentryx and Encourages Investors to Contact the Firm NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law fir...

Share this article Share this article RADNOR, Pa., May 12, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). Deadline Reminder:  Investors who purchased or acquired ChemoCentryx common stock ...

ChemoCentryx, Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit Kessler Topaz Meltzer & Check LLP Radnor, Pennsylvania, UNITED STATES RADNOR, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California ag...

Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ChemoCentryx securities between November 26, 2019 and May 3, 2021, both dates inclusive (the "Class Period"). Such investors are...

NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  - Advertisement - On May 4, 202...

Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May...

RADNOR, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action...